# Mebias Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mebias-discovery

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.mebiasdiscovery.com
- Latest round: Seed (Mar 1, 2016)
- Investors on record: 1

## About

Mebias Discovery is a biotechnology company focused on developing innovative pharmaceuticals through its proprietary membrane protein-NMR drug discovery platform, targeting G-protein coupled receptors (GPCRs) for enhanced therapeutic outcomes.Founded in 2015 in Philadelphia, US, Mebias Discovery specializes in pharmaceutical development. The company has successfully completed 4 deals, with their most recent deal occurring on October 14, 2019. They raised USD 3.5 mn in a venture funding round co-led by Sprout BioVentures and Viva Biotech (Shanghai) Ltd. The company was co-founded by Brett Tounge and Lawrence Kuo.Mebias Discovery specializes in developing innovative pharmaceuticals through its proprietary membrane protein-NMR drug discovery platform, which identifies molecules that interact with G-protein coupled receptors (GPCRs). The company is advancing an Investigational New Drug for the mu-opioid receptor, currently in Phase 1 Clinical Studies, and developing Sphingosine 1-phosphate receptor agonists for neuropathic pain and neuroinflammation. Mebias serves pharmaceutical companies and research institutions in North America, Europe, and Asia.Mebias Discovery's revenue model focuses on advancing proprietary drug candidates into clinical development through strategic partnerships with pharmaceutical firms. The company engages in B2B transactions and aims to generate returns via milestone payments and royalties as its products progress through clinical trials. Their current flagship offering, targeting the mu-opioid receptor, is central to their strategy and is anticipated to attract interest from larger pharmaceutical companies in pain management therapies.Mebias Discovery plans to leverage the USD 3.5 mn raised in October 2019 to support the clinical development of its drug candidates, particularly the mu-opioid receptor-targeting drug. The company is also exploring new markets in Europe and Asia, aiming for expansion by 2023. Upcoming product launches include additional GPCR-targeted therapeutics, which are expected to enhance their portfolio and market presence.

## Funding rounds

- Seed, Mar 1, 2016 — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed